developed a cellular system in which ATR activity can be unleashed at will, throughout the cell cycle and in the absence of any actual DNA damage 10 . The system uses a fusion of the ATR-activating domain of TopBP1 (ref. 11) with a fragment of the estrogen receptor (TopBP1 ER ). In response to an inert derivative of tamoxifen (4-hydroxy-tamoxifen; 4-OHT), TopBP1 ER translocates to the nucleus, where it promotes a generalized activation of ATR. Of note, the addition of 4-OHT promotes pan-nuclear phosphorylation of the histone H2A variant H2AX (γH2AX), which is strictly dependent on ATR and independent of ATM or DNA-PKcs 10 . Hence, examining 4-OHT induced γH2AX formation in TopBP1 ER -expressing cells provides a readout of ATR activity that is specific and easy to measure.
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To establish a screening platform, we optimized the assay in 96-well plates and automated the quantification of nuclear γH2AX signal through high-throughput microscopy (HTM) ( Fig. 1a; see Online Methods for a full description of the procedure). The screening strategy was to expose the cells to the compound to be tested for 15 min, followed by 4-OHT for 1 h more and then processing for γH2AX immunofluorescence by HTM. As a proof of principle, addition of caffeine, which is known to inhibit ATR at high concentrations, led to a stepwise decrease in the γH2AX signal (Fig. 1b) . The readouts were highly reproducible from experiment to experiment. Thus, the TopBP1 ER -based pipeline is sensitive enough to detect ATR inhibitors in a cell-based assay.
As the test library for our screening, we used a subset of 623 compounds, previously identified as having some activity toward PI3K in a screening of 33,992 small compounds 12 . Because of the similarity of PIKKs with PI3K, we reasoned that such a pool could be enriched in potential inhibitors of ATR. The initial screening, carried out at 10 µM, identified a relatively The checkpoint response of the so-called DNA damage response (DDR) relies on two members of the PI3K-related kinase (PIKK) family, ATM and ATR 1 . Whereas ATM is solely activated by DNA double-strand breaks (DSBs), ATR responds to the accumulation of single-stranded DNA (ssDNA) both at resected DSBs as well as at aberrant replicative structures that compromise genome integrity during S phase 2 . Previous work has shown evidence of an activated DDR in early stages of tumorigenesis 3, 4 . These findings led the authors to propose that oncogenes could somehow generate DNA damage through replicative stress, which would then activate the DDR and limit the expansion of precancerous cells 5 . Subsequent works confirmed that, indeed, oncogenes generate DNA damage and that the nature of this damage is linked to abnormal replication [6] [7] [8] . In other words, the oncogene-induced DDR would be a cellular response to replicative stress, which is known to be limited by ATR and its downstream kinase Chk1 (ref. 9). However, and in contrast to ATM or Chk2, ATR and Chk1 are essential in mammals, which has placed limitations on functional studies in this pathway. We describe here the identification of ATR inhibitors and the evaluation of how inhibiting ATR activity affects oncogene-expressing cells. results screening strategy One of the limitations for the discovery of inhibitors for ATR is that its kinase activity is restricted to the S and G2 phases of the cell cycle. This has hindered cell-based screening of compounds, as a large number of false positives would be identified from an indirect effect of the tested compound on the cell cycle. To overcome this limitation, we previously A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations oncogene activation has been shown to generate replication-born Dna damage, also known as replicative stress. the primary responder to replicative stress is not ataxia-telangiectasia mutated (atm) but rather the kinase atm and rad3-related (atr). one limitation for the study of atr is the lack of potent inhibitors. We here describe a cell-based screening strategy that has allowed us to identify compounds with atr inhibitory activity in the nanomolar range. Pharmacological inhibition of atr generates replicative stress, leading to chromosomal breakage in the presence of conditions that stall replication forks. moreover, atr inhibition is particularly toxic for p53-deficient cells, this toxicity being exacerbated by replicative stressgenerating conditions such as the overexpression of cyclin e. notably, one of the compounds we identified is nVP-beZ235, a dual phosphatidylinositol-3-oH kinase (Pi3K) and mtor inhibitor that is being tested for cancer chemotherapy but that we now show is also very potent against atm, atr and the catalytic subunit of Dna-dependent protein kinase (Dna-PKcs). a r t i c l e s selectivity of the inhibitors for atr versus atm and Dna-PKcs Given that the ionizing radiation-induced G2/M checkpoint is also controlled by ATM, the effects of these compounds seen in Figure 2 could be due to inhibition of other factors besides ATR. In fact, most of the available inhibitors of ATR are also potent inhibitors of ATM and DNA-PKcs. We thus determined the specificity of the two compounds against ATM, ATR and DNA-PKcs. Ionizing radiation-induced ATM and Chk2 versus Chk1 phosphorylation provide a sensitive readout of ATM and ATR activity, respectively [14] [15] [16] [17] . Likewise, ionizing radiation-induced DNA-PKcs autophosphorylation at Ser2056 provides an in vivo readout of DNA-PKcs activity 18 . Whereas both drugs potently inhibited Chk1 phosphorylation, one of them also inhibited ionizing radiation-induced ATM, Chk2 and DNA-PKcs phosphorylation, suggesting that it was an efficient inhibitor of all DDR kinases (Fig. 3a,b) . In agreement with this, whereas the ATRselective inhibitor did not affect ionizing radiation-induced γH2AX formation, which is jointly controlled by ATM and DNA-PKcs 19 , the other compound also affected this phosphorylation (Fig. 3c) . For simplicity, we will refer to these two compounds as ATRi (compound 3, ETP-46464) and DDRi (compound 7, NVP-BEZ235) from now on.
To determine whether the compounds were able to directly inhibit the kinase activities of ATM and ATR, we conducted in vitro kinase assays with immunoprecipitated Flag epitope-tagged wild-type and kinasedead versions of ATM and ATR, using a glutathione S-transferase-p53 fusion protein as a substrate ( Supplementary Fig. 1a and Supplementary Methods). Both compounds were similarly potent against ATR, but ATRi was more efficient at inhibiting ATR than ATM. In addition, we also analyzed the in vitro selectivity of these compounds against a panel of 26 kinases (Supplementary Fig. 1b) . As is the case for most kinase inhibitors, the compounds had inhibitory activity toward several other kinases. Of note, DDRi was originally described in 2008 as a dual PI3K and mTOR inhibitor with potent antitumor activity (NVP-BEZ235) 20 . Thus, we specifically calculated the in vitro half-maximal inhibitory concentration (IC 50 ) of the two compounds against recombinant PI3Kα, large set of chemicals with some ATR inhibitory capacity (Fig. 1c) . We then reanalyzed all the compounds that led to γH2AX signal lower than 30% of control values (that is, more than 70% inhibition), at different concentrations starting at 10 nM (0.01, 0.1, 1 and 10 µM). Consistent with the previous screen, most compounds showed substantial inhibitory activity at 10 µM but few showed activity below 1 µM. Notably, two compounds showed almost 100% inhibition at 100 nM, and even some response at 10 nM (Fig. 1d) . Moreover, these two molecules not only inhibited H2AX but also Chk1 phosphorylation in response to 4-OHT, strongly suggesting their ability to inhibit ATR (Fig. 1e) . We thus centered our subsequent analyses on these two compounds.
bypass of the ionizing radiation-induced g2/m checkpoint To determine whether the compounds were able of inhibiting ATR in response to actual DNA damage, we analyzed their activity in U2OS human osteosarcoma cells exposed to ionizing radiation. ATR activity contributes to the activation of the G2/M checkpoint in response to ionizing radiation, so that cells with DNA breaks do not enter mitosis 13 . Accordingly, one proposed clinical application for Chk1 inhibitors is to combine them with genotoxic agents, so that damaged cells will undergo abnormal mitosis in the absence of a proficient G2/M checkpoint. In agreement with this, and similar to what we observed in the presence of the Chk1 inhibitor UCN-01, the use of the two identified compounds abrogated the G2/M checkpoint ( Fig. 2a) and led to the presence of micronuclei or completely fragmented nuclei in cells exposed to ionizing radiation (Fig. 2b) . The structures and formal names of these two compounds are provided in Figure 2c . In contrast to the untreated cells, which readily resumed DNA synthesis, cells treated with the inhibitors were unable to do so (Fig. 4a) . This observation is consistent with fragmentation of the stalled replication forks, which would make them replication incompetent 22 . Accordingly, there was a marked increase in DSB markers, such as p53-binding protein 1 (53BP1) foci, when the inhibitors were added together with hydroxyurea ( Fig. 4b and Supplementary Fig. 3) . Moreover, and concomitant to the inhibition of Chk1 phosphorylation, cells treated simultaneously with hydroxyurea and ATRi showed elevated ATM and Chk2 phosphorylation. These phosphorylations are indicative of chromosomal breakage and were not detectable with DDRi because of the simultaneous inhibition of ATM and DNA-PKcs with this compound (Fig. 4c) . As a consequence of this damage, inhibitor-treated cells accumulated in G2 16 h after the release from hydroxyurea (Fig. 4d) .
Of note, G2 accumulation is a hallmark of ATR 23 but not ATM [24] [25] [26] or DNA-PKcs 27 deficiency, and reflects the fact that DNA damage linked to ATR inhibition occurs during S phase, so cells would arrest in the next checkpoint at G2. None of these effects could be observed with PI3K, mTOR, ATM or DNA-PKcs inhibitors (Supplementary Fig. 3 ). Altogether, these data support the idea that the ATR inhibitors identified in our screen promote the breakage of stalled replication forks.
atr-mediated suppression of replicative stress ATR activity is also necessary for replicating cells in the absence of exogenous DNA damage. Accordingly, ATR 28, 29 or Chk1 (ref. 30, 31) deletions lead to early embryonic lethality in the mouse. The reason for this essential nature is that ATR and Chk1 prevent spontaneous replicative stress during S phase. In mammalian cells, the presence of replicative stress can be detected by a pan-nuclear phosphorylation of H2AX, which contrasts with the punctate pattern observed at DSBs. This pan-nuclear staining can be readily detected upon treatment with Chk1 inhibitors 32 and is also widespread in embryos and mouse embryo fibroblasts (MEFs) from a hypomorphic ATR mouse strain (ATR-Seckel) 23 . We thus evaluated whether these inhibitors were capable of inducing replicative stress. Indeed, both compounds led to the appearance of cells with mTOR and DNA-PKcs, as well as the in vitro IC 50 for immunoprecipitated ATM and ATR as described above (Supplementary Fig. 1c) . Both compounds presented substantial activity against ATM, ATR, PI3Kα, mTOR and DNA-PKcs, although ATRi was less effective against ATM and DNA-PKcs. Notably, ATRi was even more selective for ATR versus ATM and DNA-PKcs in cellulo than it was in vitro (Fig. 3) . This is not unusual for kinase inhibitors: for example, the tyrosine kinase inhibitor NVP-AEW541 is equally potent against the kinases IGF-IR and InsR in vitro, but it is 26-fold more selective against IGF-IR in cellulo, a property that has been explored for cancer chemotherapy 21 . In vivo, the IC 50 values for ATR inhibition calculated with the ATR-specific assay were 100 nM for DDRi and 25 nM for ATRi (Supplementary Fig. 2 ).
Destabilization of stalled replication forks
We next characterized the cellular effects of these compounds, focusing on those that are known to be associated to ATR deficiency and not to ATM, DNA-PKcs, PI3K or mTOR. One of the best established roles of ATR, which is not shared by ATM or DNA-PKcs, is preventing the collapse of stalled replication forks 9 . To test this, we exposed U2OS cells to hydroxyurea (which promotes fork stalling because of dNTP depletion) for 3 h, in the presence or absence of the inhibitors, and then transferred ATRi (µM)
Chk1 Ponceau c a r t i c l e s induced by hydroxyurea (Supplementary Fig. 6a) . On the contrary, the replicative stress-associated pan-nuclear γH2AX signal was abrogated in the presence of ATM and DNA-PKcs inhibitors ( Supplementary  Fig. 6b ), as previously shown for ATR-Seckel MEFs 23 . This might explain why the induction of γH2AX by hydroxyurea was weaker with DDRi than with ATRi, whereas other effects associated with replicative stress (lethality, RPA foci, G2 arrest, 53BP1 foci in response to hydroxyurea or the recovery of stalled replication forks) occurred to at least the same degree. Altogether, these results support the idea that the compounds identified in this screen are bona fide ATR inhibitors.
atr inhibition in the presence of oncogene-induced replicative stress Previous evidence showed that limiting ATR 23, 34 or Chk1 (ref. 35 ) functions is particularly toxic for p53-deficient cells. We recently showed that, in conditions of limited ATR function, increased replication rates linked to p53 absence lead to even higher replicative stress 23 . In agreement with this, the degree of replicative stress generated by the inhibitors was further increased in p53-deficient MEFs (Fig. 5e,f) . If our interpretation is correct, targeting ATR or Chk1 should be more toxic not only in the presence of p53 deficiency but also in the presence of other mutations that promote replicative stress. To test this idea, we analyzed the effect of the inhibitors on cyclin E-overexpressing cells, alone or in combination with the absence of p53. We chose cyclin E overexpression for two reasons: first, this is a common event in human carcinomas; second, previous data have already shown that cyclin E overexpression can generate DNA damage 3, 36, 37 .
We initially tested whether cyclin E overexpression led to replicative stress in MEFs. We first conducted our experiments in primary MEFs, as human cell lines contain several other mutations that could confound the interpretation of the data. Infection with a cyclin E-expressing retrovirus indeed led to the appearance of cells with a pan-nuclear staining of γH2AX (Fig. 6a) . The amount of cyclin E-induced replicative stress was further increased by ATR inhibitors, and the effect was more pronounced in p53-deficient MEFs (Fig. 6b) . The clinical relevance of this approach is that, as previously shown, replicative stress-induced apoptosis is independent of p53 (refs. 23, 34, 35, 38, 39) . Moreover, whereas cyclin E overexpression in MEFs is not proapoptotic per se, it led to a marked increase in the apoptotic elimination of the cells when combined with ATR inhibitors and p53 absence (Fig. 6c) . This response was further boosted by UCN-01, consistent with the apoptosis being due to replicative stress. In contrast, this selective and p53-independent toxicity of ATR inhibitors toward cells overexpressing cyclin E was not observed upon inhibition of PI3K or mTOR, not even when both signaling pathways were simultaneously targeted with a dual PI3K and mTOR inhibitor (Supplementary Fig. 7a,b) . We made similar observations in human pan-nuclear γH2AX, although not as many as with UCN-01 (Fig. 5a,b) . As further proof that the pan-nuclear γH2AX staining indicates replicative stress, this staining pattern was restricted to S-phase cells (Supplementary Fig. 4a ). In addition, the use of the inhibitors also led to the accumulation of replication protein A (RPA) foci ( Supplementary  Fig. 4b,c) . As to how ATR inhibition could lead to the generation of replicative stress, a recent report revealed that the S-phase-restricted γH2AX observed in the presence of Chk1 inhibitors was dependent on the cell cycle regulatory phosphatase CDC25A 33 . In fact, RNA interference-mediated depletion of CDC25A substantially limited the amount of replicative stress induced by our ATR inhibitors ( Supplementary  Fig. 4d,e) . Thus, these data reveal that the exposure to the inhibitors leads the generation of substantial amounts of DNA damage in replicating cells, which are dependent on the Chk1 target CDC25A.
We next explored whether the use of low doses of the inhibitors could boost the levels of replicative stress in the presence of other conditions that generate it, such as hydroxyurea or UCN-01. Indeed, the addition of either compound to hydroxyurea-or UCN-01 treated cells led to a further increase in replicative stress (Fig. 5c,d) , suggesting that combining these drugs could potentiate their cytotoxic effects. Moreover, the use of low doses of ATR inhibitors, at concentrations at which they do not generate detectable replicative stress, enhanced the effects of low doses of UCN-01 (Supplementary Fig. 5 ). This effect is relevant in the context of in vivo uses of Chk1 or ATR inhibitors, as reaching pharmacologically effective doses of a given compound is a common problem. Notably, inhibitors of PI3K, mTOR, ATM or DNAPKcs, did not generate replicative stress, and nor did they enhance that Figure 4 ATRi and DDRi promote the breakage of stalled replication forks. (a) The capability to restart DNA synthesis from stalled replication forks was quantified by a pulse of 5-ethynyl-2´-deoxyuridine (EdU) (1 h), carried out at different times after the release from a 3-h exposure to hydroxyurea. Whereas replication can readily restart in control U2OS cells, the presence of either inhibitor stops fork progression. PI, propidium iodide. (b) Cells taken from a were stained for 53BP1 to visualize the presence of DNA breaks 16 h after the release from hydroxyurea. The presence of the ATR inhibitors together with hydroxyurea leads to a very high accumulation of DNA breaks. (HTM quantification of these data is available in Supplementary Fig. 2 
should try to limit this effect. Most importantly, as reported in this work, not even dual inhibition of PI3K and mTOR showed a synthetic lethal effect with cyclin E overexpression and/or p53 deficiency. Recent data have shown that NVP-BEZ235 is a potent radiosensitizing compound for Ras-overexpressing tumors 43 , an effect which seems more likely to be mediated by inhibition of the DDR kinases rather than PI3K or mTOR. In agreement with this, a recent report revealed that RNAi-mediated depletion of ATR is particularly toxic for cells overexpressing oncogenic Ras 44 . In summary, we believe that much of the potential of this drug for cancer chemotherapy could be due to its potent effect on ATR, and this information should be used for rational design of clinical studies using NVP-BEZ235.
The high levels of replicative stress present in some cancer cells might also expose them to therapies directed to further compromise genomic integrity, as already proposed in previous works 5, 45 . In fact, targeting DNA repair activities has emerged as a promising approach for cancer chemotherapy, a concept that was fueled by the discovery of a selective toxicity of poly-ADP-ribose polymerase (PARP) inhibitors for tumors carrying BRCA1 or BRCA2 mutations 46, 47 . However, with regard to DDR signaling specifically, most efforts have focused in understanding how the oncogene-induced DDR might protect us from cancer through the activation of p53-dependent apoptosis and senescence. In this context, targeting the DDR kinases could be seen as counterproductive because it could fuel cancer development by eliminating this anticancer barrier. primary foreskin fibroblasts (BJ cells), although the toxicity of ATR inhibitors was lower, probably owing to the slower proliferation of these cells ( Supplementary Fig. 7c,d) . Altogether, these results show that targeting the cellular response against replicative stress sensitizes cells harboring cancer-associated mutations that promote replicative stress.
Discussion
We here describe a pipeline to successfully identify inhibitors of ATR and describe two of the most potent compounds identified in this screen. As mentioned, the in vivo IC 50 for ATR inhibition was 100 nM for DDRi and 25 nM for ATRi. It should be noted that this IC 50 was determined in cellulo, where IC 50 values are usually higher than in vitro because of compound permeability and other availability issues. For our cellular assays, the inhibitors were used at 1-5 µM. As a measure of their activity, widely accepted potent inhibitors of ATM (KU5593) 40 or DNA-PKcs (NU7026) 41 are normally used at 5-10 and 20-30 µM, respectively; and the recently described ATR inhibitor schisandrin B is used at 30 µM for cellular assays 42 .
In addition to their potency, the two compounds were selected for the following reasons. The ATRi was selected on the basis of the academic interest in providing a potent ATR inhibitor, which is selective for ATR versus ATM and DNA-PKcs even at high doses. The chemical synthesis route of ATRi is also provided here, to allow its production in other laboratories (Supplementary Fig. 8) . Unfortunately, ATRi has poor pharmacological properties in mice, which limit its use for therapy. In contrast, studying the effects of DDRi has an important clinical perspective: this compound is already been studied and tested in clinical trials as a dual PI3K and mTOR inhibitor, under the name of NVP-BEZ235 (ref. 20) . In fact, and as is the case in most PIKK inhibitors available, the compound does show potent activity toward PI3K and mTOR. However, neither PI3K nor mTOR inhibitors showed any of the replicative-stress associated effects seen with ATR inhibitors, including the generation of RPA foci, G2 arrest or destabilization of stalled forks. On the contrary, the antiproliferative activity due to mTOR inhibition possessed by ATRi and DDR is counterproductive for the generation of replicative stress, and future efforts in improving these compounds In agreement with this, mutations in p53 pathway genes are mutually exclusive with ATM mutations in human cancers 48 . In contrast to ATM, we here show that ATR inhibition is particularly toxic for cells presenting oncogene-induced replicative stress, eliminating these cells through p53-independent apoptosis. We do not believe that all tumors, or all cancerassociated mutations, have the same degree of replicative stress. However, measuring replicative stress in tumor biopsies is affordable. This could be done, for instance, by quantifying the percentage of cells showing a pan-nuclear distribution of γH2AX on biopsies, which we propose could be used in the future as a predictive biomarker of the potential efficacy of ATR and Chk1 inhibitors in the clinic. a r t i c l e s
